No difference in between-country variability in use of newly approved orphan and non- orphan medicinal products - a pilot study
<p>Abstract</p> <p>Background</p> <p>Regulators and payers have to strike a balance between the needs of the patient and the optimal allocation of resources. Drugs indicated for rare diseases (orphan medicines) are a special group in this context because of their often...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2009-12-01
|
| Series: | Orphanet Journal of Rare Diseases |
| Online Access: | http://www.ojrd.com/content/4/1/27 |